1. Eckl,K.M.: Untersuchungen zur Struktur und Funktion von Cuticula-membranen. Diplom-Arbeit zur Erlangung des akademischen Grades Diplom-Physiker der Fakultät für Experimentelle Physik der Universität Ulm 1979.
2. Schönherr,J., Eckl,K.M., Gruler,H.: Water Permeability of Plant Cuticles: The Effect of Temperature on Diffusion of Water. Planta 1979; 147: 21-26.
3. Eckl,K.M., Gruler,H.: Phase Transitions in Plant Cuticles. Planta 1980; 150: 102-113.
4. Eckl,K.M.: Erythrocyten als Indikatorzellen bei Krankheiten mit Zellmembrandefekt, am Beispiel der Paramyotonia congenita. Inaugural-Dissertation zur Erlangung der Doktorwürde der Medizin der Fakultät für Theoretische Medizin der Universität Ulm 1982.
5. Eckl,K.M., Greb,W.H.: Potassium Channel activation in the Vascular Smooth Muscle Cell Membrane - a New Mechanism of Action in Antihypertensive Treatment - Early Clinical Results with BRL 34915. Clin.Exp.Hyperten. 1987; A 49 (1): 160.
6. Eckl,K.M., Gruler,H.: Description of Cell Adhesion by Langmuir Adsorption Isotherm. Z.Naturforsch. 1988; 43c.
7. Davies,B.E., Dierdorf,D., Eckl,K.M., Greb, W.H., Mellows,G., Thomsen,T.: The pharmacokinetics of BRL 34915, a new antihypertensive agent, in healthy male subjects. Br.J.Clin.Pharmacol. 1988; 25: 136-137.
8. Krastev,Z., Terziivanov,D., Vlahov,V., Maleev,A., Eckl,K.M., Dierdorf,D., Greb, W.H., Wolf,D.: Pharmacokinetics of Paroxetine in Patients with Liver Cirrhosis. Acta Psychiatr.Scand. 1988; 80, (suppl. 350): 160.
9. Eckl,K.M., Greb,W.H.: The Effect of BRL 34915 in Patients with High Blood Pressure. Z.Kardiol. 1988; 77: 478.
10. Greb,W.H., Dierdorf,D., Hust,R., Mayer, M.E.R., v. Schrader,H.W., Wolf,D., Freude,J., Haeringer,E.P., Hoffmann,K., Kerler,F., Panijel,M., Schedemantel,V., Eckl,K.M.: Efficacy of Diproteverine in Patients with Stable Angina Pectrois. Fall Meeting DGPT, Hamburg. Naunyn-Schmiedeberg's Arch.Pharmacol. 1988; Suppl.: Abstract R83.
11. Eckl,K.M., Stoeter,M., Möller,M., Wargenau,M.: Conjunctival capillaroscopy as a method for investigation of drugs with vasodilative properties. Spring meeting DGPT, Mainz, 10.-12.03.1992. Naunyn-Schmiedeberg´s Arch.Pharmacol. 1992; Vol. 345: 20.
12. Stoeter,M., Möller,M., Eckl,K.M., Wargenau,M.: Conjunctival capillaroscopy allows to quantify vasodilative effects of nifedipine, captopril, and moxaverine. 14th Congress of the European Society of Cardiology, Barcelona, Spain, 30.08.-03.09.1992. Europ.Heart.J. 1992; 13, Suppl.: 199.
13. Dennis,M.J., Dierdorf,H.D., Erdmann,M., Collie,H., Eckl,K.M.: The potassium channel activator BRL 38227 demonstrates linear pharmacokinetics with low intersubject variability. Autumn meeting DGPT, Graz, 06.-09.09. Naunyn-Schmiedeberg´s Arch.Pharmacol. 1992; Abstracts.
14. Beerahee,A., Taylor,A.C., Kaye,C.M., Dierdorf,H.D., Eckl,K.M.: Pharmacokinetic profile of levchromakalim, a novel antihypertensive agent, following intravenous administration in healthy male volunteers. British Pharmacological Society Meeting, 07.-11.09.1992, London. Abstracts.
15. Eckl,K.M., Stoeter,M., Möller,M., Collie,H.: Die periphervasodilatorischen Eigenschaften von BRL 38227 - Nachweis an gesunden Probanden. Zweite gemeinsame Tagung Deutsche Liga zur Bekämpfung des hohen Blutdruckes und Schweizerische Vereinigung gegen hohen Blutdruck, Zürich 26.-28.11.1992. Abstracts.
16. Thomsen,T., Eckl,K.M., Möller,M., Knieps-Massong,W., Hucke,H.P., Schlieper,P.: Relative Bioverfügbarkeit einer neuen galenischen Formulierung von Thyroxin und Iodid: Thyreocomb N, Therapiewoche 1996; 46, Heft 3: 32.
17. Thomsen,T., Eckl,K.M., Möller,M., Knieps-Massong,W., Hucke,H.P.: Evaluation of the pharmacokinetics and pharmacodynamics of Thyreocomb N(, a new galenic formulation of thyroxine and iodide. Spring meeting DGPT, Mainz, 12.-14.03.1996. Naunyn-Schmiedeberg's Arch.Pharmacol. 1996; Suppl. to Vol. 353: R 146.
18. Thomsen,T., Eckl,K.M., Möller,M., Hucke,H.P.: Noninvasive continuous blood pressure measurement as a tool for estimating the interaction of monoaminooxidase inhibitors with tyramine. Spring meeting DGPT, Mainz, 12.-14.03.1996 Naunyn-Schmiedeberg's Arch.Pharmacol. 1996; Suppl. to Vol. 353: R 140.
19. Püchler,K., Eckl,K.M., Fritsche,L., Renneisen,K., Neumayer,H., Sierakowski,B., Lavrijssen,A.J.C., Thomsen,T.: Repeat dose pharmacokinetics of temocapril (T) in renally impaired subjects. 6th World Conference on Clinical Pharmacology and Therapeutics, 04.-09.08.1996. Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; Abstract Book: 242 No. 555.
20. Eckl,K.M., Römer,A., Kleist,P., Suzuki,Y., Thomsen,T.: Pharmacokinetics of captopril unchanged by concomitant medication of voglibose (AO-128). 6th World Conference on Clinical Pharmacology and Therapeutics, 04.-09.08.1996. Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; Abstract Book: 242 No. 556.
21. Eckl,K.M., Thomsen,T., Römer,A., Hucke,H.P., Kurowski,M., Kleist,P., Suzuki,Y.: No interaction of the disaccharidase inhibitor AO-128 (Voglibose) with hydrochlorothiazide. Autumn Meeting DGPT, Dresden, 10.-12.09.1996. Naunyn-Schmiedeberg's Arch.Pharmacol. 1996; Suppl. No.1 to Vol. 354: R 30.
22. Thomsen,T., Eckl,K.M., Möller,M., Drachenberg,J.: Keine Sensibilisierung durch multiple Dosen von modifiziertem Allergen (Allergoid) bei gesunden Probanden. 20. Tagung der Deutschen Gesellschaft für Allergie- und Immunitätsforschung, Konzerthaus Freiburg, 02.-05.10.1996. MMV Medizin Verlag, Allergo J. 1996; Vol. 5: P33.
23. Thomsen,T., Eckl,K.M., Römer,A., Peck,C.C., Dehn,A.: Terfenadine drug interaction. PK/PD and non-responders. Spring meeting AGAH, Ulm, 30.01.-05.02.1997. Poster presentation.
24. Eckl,K.M., Thomsen,T., Hucke,H.P., Kleist,P., Suzuki,Y., Möller,M.: Cholestyramine does not impair the effects of voglibose (AO-128) on glucose and insulin. 16th International Diabetes Federation Congress, Helsinki, Finland, 20-25.07.1997. Diabetologia 1997; Vol. 40, Supplement 1: Abstract No. 1281.
25. Eckl,K.M., Thomsen,T., Möller,M., Violet,I., Dubois,F.: The bradycardic effect of the sinuatrial modulator S 16257. European Society of Cardiology. Stockholm, Sweden, 24-28.08.1997. European Heart Journal 1997; Vol. 18, Suppl.: Abstract No.P1047.
26. Püchler,K., Eckl,K.M., Fritsche,L., Renneisen,K., Neumayer,H., Sierakowski,B., Lavrijssen,A.J.C., Thomsen,T., Roots,I.: Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Brit.J.Clin.Pharmacol., 1997; Vol.44: 531-536.
27. Thomsen,T., Püchler,K., Eckl,K.M., Plenker,A., Möller,M., Hucke,H.P.: Cardiovascular safety of the monoaminooxidase inhibitor (MAO-I) RS-8359 in combination with intravenous tyramine. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, 17-20.09.1997, Berlin, Germany. Europ.J.Clin.Pharmacol. 1997; Suppl. to Vol. 52: Abstract No. 436.
28. Sierakowski,B., Püchler,K., Neumayer,H.H., Fritsche,L., Eckl,K.M., Witte,P.U., Roots,I.: Single dose and multiple dose pharmacokinetics of temocapril and temocaprilat in renally impaired subjects. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, 17-20.09.1997, Berlin, Germany. Europ.J.Clin.Pharmacol. 1997; Suppl. to Vol. 52: Abstract No.130.
29. Kleist,P., Suzuki,Y., Thomsen,T., Möller,M., Römer,A., Hucke,H.P., Kurowski,M., Eckl,K.M.: Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Europ.J.Clin.Pharmacol. 1998; Vol.54: 273-274.
30. Thomsen,T., Brockmöller,J., Popescu,G., Hucke,H.P., Eckl,K.M., Roots,I.: No effect of liver impairment on the pharmacokinetics of levetiracetam. Annual Congress of Clinical Pharmacology, 10-12.06.1999, Berlin, Germany. Europ.J.Clin.Pharmacol. 1999; Vol.55: Abstract No.91.
31. Eckl, K.M., Thomsen, T., Römer A., Dehn, A.: Terfenadine induced QTc-Prolongation in healthy subjects - a safety model. Annual Congress of Clinical Pharmacology, 10.-12.06.1999, Berlin, Germany. Europ.J.Clin.Pharmacol. 1999; Vol.55: Abstract No.108.
32. Wadepuhl,M., Thomsen,T., Drachenberg,J., Möller,M., Eckl,K.M.: Tolerability and immunological activity of monophosphoryl lipid A in specific immunotherapy.28th annual meeting of the American College of Clinical Pharmacology, 16.-18.09.1999, Rockville, MD, USA. The J.Clin.Pharmacol. 1999; Vol.39, No.9: Abstract No.47.
33. Thomsen,T., Brockmöller,J., Eckl,K.M., Wittstock,M., Roots,I.: Usefulness of Child Pugh classification to select patients with liver impairment for clinical trials. 3rd Congress of the European Association for Clinical Pharmacology, 03.-08.10.1999, Jerusalem, Israel. British J.Clin.Pharmacol. 1999; Abstracts of the joint meeting, 41/42.
34. Eckl,K.M., Jungheinrich,C., Scharpf,R., Bepperling,F., Wargenau,M.: Pharmacokinetics and tolerability of a new hydroxyethyl starch specification 6 % HES 130/0.4 (Voluven(r)) after single-dose infusion in subjects with renal impairment. Deutscher Anästhesiekongress - DAK International - 06.-09.05.2000, Poster Presentation.
35. Thomsen T., Eckl K. M. (2002): Praktische, klinisch-pharmakologische Tätigkeit am Probanden und Patienten (Phase I) in: Kompendium der Klinischen Pharmakologie, Charlotte Herrlinger, Willi Cawello (Hrsg.). Shaker Verlag, Aachen 2002: 517-554.
36. Eckl K.M., Sydorchuk L., Biletski S., Tsvitbaum N., Wadepuhl M., Thomsen T., Darius H.: The reliability of QTc interval assessment. BMC Meeting Abstracts: 2003 Annual Meeting of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology) 2003; 2: P0002.
37. Eckl K.M. Tsvitbaum N., Donath F., Biletski S., Sydorchuk L.: The effect of propiverine on cardiac safety in healthy female subjects: A double-blind, placebo-controlled, randomised trial. Am. J. Hypertension, 2003; Vol 15 No 5, Part 2: P-618.
38. Sydorchuk L., Tsvitbaum N., Donath F., Biletski S., Eckl K.M.: The Cardiac Safety of Propiverine-HCL (Mictonorm(r)) Assessed in Female Subjects. Proceedings of the 5th International Congress on Coronary Artery Disease, 2003: p. 521-526.
